An experimental oral medication reduced the risk of hospitalization and death from covid by 50% in an interim clinical trial. The drug, named molnupiravir, was developed by Merck and Ridgeback Biotherapeutics, who will now proceed immediately to securing emergency use authorization. — Read the rest
